Jump to content

Ozoralizumab

From Wikipedia, the free encyclopedia
Ozoralizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
Clinical data
Trade namesNanozora
ATC code
  • none
Legal status
Legal status
  • Rx in Japan
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC1682H2608N472O538S12
Molar mass38434.85 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Ozoralizumab (trade name Nanozora) is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases.[1]

Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV. Ablynx has licensed the rights to the antibody in China to Eddingpharm. In 2022, ozoralizumab was approved in Japan for the treatment of rheumatoid arthritis.[2]

References

[edit]
  1. ^ Kratz F, Elsadek B (July 2012). "Clinical impact of serum proteins on drug delivery". J Control Release. 161 (2): 429–45. doi:10.1016/j.jconrel.2011.11.028. PMID 22155554.
  2. ^ "Notification of Approval to Manufacture and Market Nanozora® 30mg Syringes for S.C. Injection, a Therapy for Rheumatoid Arthritis, in Japan Japan's First NANOBODY® Therapeutic" (Press release). Taisho Pharmaceutical Holdings. September 26, 2022.